Fujirebio and Sysmex Collaborate for Development and Advancement of Immunoassay

By LabMedica International staff writers
Posted on 18 Dec 2023

Image: Fujirebio and Sysmex have signed an agreement for the supply of reagent raw materials in the field of immunoassay (Photo courtesy of 123RF)

Image: Fujirebio and Sysmex have signed an agreement for the supply of reagent raw materials in the field of immunoassay (Photo courtesy of 123RF)

Fujirebio Holdings (Tokyo, Japan) and Sysmex Corporation (Kobe, Japan) have signed an agreement for the mutual supply of reagent raw materials owned by both companies. The agreement is based on a basic agreement on business collaboration in the field of immunoassay signed by the two companies in October 2023.

In October 2023, Fujirebio and Sysmex entered into a basic agreement on business collaboration in the field of immunoassay, intending to promote cooperation to accelerate their global expansion, and to contribute to the development and advancement of immunoassay. To promote specific initiatives, the two companies signed a Contract Development and Manufacturing Organization (CDMO) agreement in November 2023 related to dedicated reagents for the HISCL-Series automated immunoassay system, involving the development of reagents for cerebral-spinal fluid-based and blood-based testing in the field of neurodegenerative diseases, including Alzheimer’s disease.

As per the terms of the agreement, Fujirebio and Sysmex will mutually supply a wide range of reagent materials owned by each company, primarily antigens and antibodies, which are the key raw materials of immunoassay reagents. This will allow the CDMO to speed up reagent development, lower costs, and maximize the value of raw material assets while building a stable supply system to meet the global demand growth in the future and prepare for raw material procurement risk in case of an emergency. By strengthening cooperation in the area of reagent materials, Fujirebio and Sysmex will promote the mutual utilization of their high-quality reagent materials. Additionally, they will continue to work together in the future to develop new parameters and technologies.

Related Links:
Fujirebio Holdings
Sysmex Corporation

Visit expo >

Gold Member

Collection and Transport System

PurSafe Plus®

POC Helicobacter Pylori Test Kit
Hepy Urease Test

Human Estradiol Assay

Human Estradiol CLIA Kit

CBM Analyzer

Complete Blood Morphology (CBM) Analyzer

Latest Industry News

Channels

Clinical Chemistry

view channel

New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment

Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more

Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients

Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read more

Study Compares Analytical Performance of Quantitative Hepatitis B Surface Antigen Assays

Hepatitis B virus (HBV) continues to pose a significant global health challenge, with chronic infection affecting hundreds of millions of people despite effective vaccines and antiviral therapies.... Read more

Blood Test Could Predict and Identify Early Relapses in Myeloma Patients

Multiple myeloma is an incurable cancer of the bone marrow, and while many patients now live for more than a decade after diagnosis, a significant proportion relapse much earlier with poor outcomes.... Read more

Molecular Diagnostics

view channel

Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability

Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more

“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies

Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more

Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis

Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read more

Hematology

view channel

New Guidelines Aim to Improve AL Amyloidosis Diagnosis

Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more

Image: The new device can fit in the palm and is capable of measuring the quality of red blood cells (Photo courtesy of Xiaoyun Ding)

Fast and Easy Test Could Revolutionize Blood Transfusions

Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more

Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow

High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more

Image: Characterizing early thrombin generation in cardiovascular disease with a high-sensitivity coagulation assay (Akira Fujiyama, et al., J. Thromb. Haemost., DOI: 10.1055/a-2751-8379)

High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients

Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read more

Immunology

view channel

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response

Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more

Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs

Colon cancer remains a major cause of cancer-related illness, with many patients facing relapse even after surgery and chemotherapy. Up to 40% of people with stage III disease experience recurrence, highlighting... Read more

Microbiology

view channel

Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens

Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more

New Test Measures How Effectively Antibiotics Kill Bacteria

Antibiotics are typically evaluated by how well they inhibit bacterial growth in laboratory tests, but growth inhibition does not always mean the bacteria are actually killed. Some pathogens can survive... Read more

New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics

Antibiotic resistance is rising worldwide, threatening the effectiveness of treatments for major infectious diseases, including tuberculosis (TB). Resistance to key TB drugs, such as bedaquiline, is of... Read more

Pathology

view channel

Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy

Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more

Image: The new test analyzes cellular signaling dysfunctions to assess autism risk shortly after birth (Photo courtesy of NeuroQure)

First-Of-Its-Kind Test Identifies Autism Risk at Birth

Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read more

AI Algorithms Improve Genetic Mutation Detection in Cancer Diagnostics

Accurately identifying genetic mutations is central to cancer diagnostics and genomic research, but current methods struggle with complex sequencing data and limited clinical samples. Tumor analysis often... Read more

Skin Biopsy Offers New Diagnostic Method for Neurodegenerative Diseases

Transthyretin amyloidosis (ATTR) is a rare, progressive, and highly aggressive disease caused by the misfolding of a specific protein that accumulates as toxic amyloid filaments in multiple organs.... Read more

Technology

view channel

Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals

Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read more

Aptamer Biosensor Technology to Transform Virus Detection

Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more

AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests

Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read more